ValuEngine upgraded shares of BTG (OTCMKTS:BTGGF) from a sell rating to a hold rating in a research note published on Friday morning.

Separately, Zacks Investment Research raised BTG from a sell rating to a hold rating in a research note on Friday, May 18th.

Shares of BTG stock traded up $0.45 on Friday, hitting $7.45. The company had a trading volume of 580 shares, compared to its average volume of 978. BTG has a 1 year low of $6.15 and a 1 year high of $10.88.

About BTG

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.

Featured Article: Hedge Funds – Risk or Reward?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with's FREE daily email newsletter.